<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H4C41E6F7E04B47078D23FC4CA2D6C3A0" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 4299 IH: Improving Regulatory Transparency for New Medical Therapies Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2014-03-26</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4299</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140326">March 26, 2014</action-date>
			<action-desc><sponsor name-id="P000373">Mr. Pitts</sponsor> (for himself and <cosponsor name-id="P000034">Mr. Pallone</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the <committee-name committee-id="HJU00">Committee on the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Controlled Substances Act with respect to drug scheduling recommendations by the
			 Secretary of Health and Human Services, and with respect to registration
			 of manufacturers and distributors seeking to conduct clinical testing.</official-title>
	</form>
	<legis-body id="H3D7856030F154CAB9CA7B3EE1120FC3D" style="OLC">
		<section id="H50C178AFA00F4508B6D6A6560D7B53ED" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Improving Regulatory Transparency for New Medical Therapies Act</short-title></quote>.</text>
		</section><section id="H99F61C2A5E3C4A798F9F2149DD18DFE0"><enum>2.</enum><header>Scheduling of substances included in new FDA-approved drugs</header><text display-inline="no-display-inline">Section 201 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811</external-xref>) is amended by inserting after
			 subsection (h) the following:</text>
			<quoted-block id="HF92623B6E0604C849F1CB660CB9CF7B9" style="OLC">
				<subsection id="H956A198CA01D4E9699386C70F5CD2DFE"><enum>(i)</enum><text display-inline="yes-display-inline">Within 45 days of receiving a recommendation from the Secretary to add a drug or substance that has
			 never been marketed in the United States to a schedule under this title,
			 the Attorney General shall, without regard to the findings required by
			 subsection (a) of this section or section 202(b), issue an interim final
			 rule, under the exception for good cause described in subparagraph (B) of
			 <external-xref legal-doc="usc" parsable-cite="usc/5/553">section 553(b)</external-xref> of title 5, United States Code, placing the drug or
			 substance into the schedule recommended by the Secretary. The interim
			 final rule shall be made immediately effective under section 553(d)(3) of
			 title 5, United States Code.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
		</section><section id="H3DB6FFA0B1A74E0EB1E5F0DD55D30F01"><enum>3.</enum><header>Enhancing new drug development</header><text display-inline="no-display-inline">Section 302 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822</external-xref>) is amended by inserting after
			 subsection (g) the following:</text>
			<quoted-block id="HC162F4D7FAF94B0AA24C8186367E9B1A" style="OLC">
				<subsection id="HF2A73ADF44F54B218F20AFB7008F5C92"><enum>(h)</enum>
					<paragraph commented="no" display-inline="yes-display-inline" id="HDD63E7052F8E473FA3B96EE446648EDB"><enum>(1)</enum><text>A person who submits an application for registration to manufacture or distribute a controlled
			 substance in accordance with this section may indicate on the registration
			 application that the substance will be used only in connection with
			 clinical trials of a drug in accordance with section 505(i) of the Federal
			 Food, Drug, and Cosmetic Act.</text>
					</paragraph><paragraph id="H651AEA7933CD43319C7BA55231DE9DD9" indent="up1"><enum>(2)</enum><text>When an application for registration to manufacture or distribute a controlled substance includes
			 an indication that the controlled substance will be used only in
			 connection with clinical trials of a drug in accordance with section
			 505(i) of the Federal Food, Drug, and Cosmetic Act, the Attorney General
			 shall—</text>
						<subparagraph id="H3942D2C99E324569A4794CC20039393A"><enum>(A)</enum><text>make a final decision on the application for registration within 180 days; or</text>
						</subparagraph><subparagraph id="HBC6ACE82E98E4FE39214CD01729720E1"><enum>(B)</enum><text>provide notice to the applicant in writing of—</text>
							<clause id="H41FD75B83D884EF2A12A07311FF5C866"><enum>(i)</enum><text>the outstanding issues that must be resolved in order to reach a final decision on the application;
			 and</text>
							</clause><clause id="H1050D99947004C93B7AE35C5AF3884B1"><enum>(ii)</enum><text>the estimated date on which a final decision on the application will be made.</text>
							</clause></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
</bill>


